Table II.
Patient and tumour characteristics.
| Characteristic | Patients | |
|---|---|---|
| N | % | |
| Age | 43-77 | |
| Mean | 62 | |
| Range | ||
| Sex | ||
| Male | 16 | 80 |
| Female | 4 | 20 |
| ECOG Status | ||
| 0 | 16 | 80 |
| 1 | 4 | 20 |
| Smoking Status | ||
| No | 8 | 40 |
| < 1 packet | 7 | 35 |
| >1 packet | 5 | 25 |
| Alcohol Intake | ||
| No | 9 | 45 |
| < 1 litre/day | 7 | 35 |
| > 1 litre/day | 4 | 20 |
| HPV Status * | ||
| Negative | 7 | 50 |
| Positive | 2 | 14 |
| Unknown | 5 | 36 |
| Primary Site | ||
| Tonsil | 7 | 35 |
| Base of tongue | 5 | 25 |
| Soft palate | 2 | 10 |
| Nasopharynx | 6 | 30 |
| T Stage | ||
| 1 | 4 | 20 |
| 2 | 8 | 40 |
| 3 | 3 | 15 |
| 4 | 5 | 25 |
| N Stage | ||
| 0 | 7 | 35 |
| 1 | 3 | 15 |
| 2 | 10 | 50 |
| AJCC Stage ** | ||
| II | 6 | 30 |
| III | 4 | 20 |
| IV | 10 | 50 |
| Medical therapy | ||
| None | 4 | 20 |
| Cisplatin | 13 | 65 |
| Cetuximab | 3 | 15 |
*
HPV status was assessed for patients with oropharynx cancer
**
AJCC Stage = American Joint Committee on Cancer